Published in Clin J Am Soc Nephrol on November 18, 2010
Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant (2014) 1.55
Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol (2013) 1.26
Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol (2014) 1.24
Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis (2012) 1.01
Rationale for early treatment of polycystic kidney disease. Pediatr Nephrol (2014) 0.91
Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant (2012) 0.89
Urine osmolarity and risk of dialysis initiation in a chronic kidney disease cohort--a possible titration target? PLoS One (2014) 0.89
Kidney volume and function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol (2013) 0.87
New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol (2013) 0.85
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol (2015) 0.84
Clinical utility of PKD2 mutation testing in a polycystic kidney disease cohort attending a specialist nephrology out-patient clinic. BMC Nephrol (2012) 0.81
Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease. PLoS One (2014) 0.80
Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry. BMC Nephrol (2013) 0.80
The Treatment of Autosomal Dominant Polycystic Kidney Disease. Dtsch Arztebl Int (2015) 0.80
A young patient with a family history of hypertension. Clin J Am Soc Nephrol (2014) 0.79
Diet and polycystic kidney disease: A pilot intervention study. Clin Nutr (2016) 0.79
The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol (2016) 0.76
Experimental therapies and ongoing clinical trials to slow down progression of ADPKD. Curr Hypertens Rev (2013) 0.76
Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol (2015) 0.75
Experiences and Perspectives of Polycystic Kidney Disease Patients following a Diet of Reduced Osmoles, Protein, and Acid Precursors Supplemented with Water: A Qualitative Study. PLoS One (2016) 0.75
Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int (2016) 0.75
Diagnostic Algorithm in the Management of Acute Febrile Abdomen in Patients with Autosomal Dominant Polycystic Kidney Disease. PLoS One (2016) 0.75
Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus. Can J Kidney Health Dis (2017) 0.75
Influence of angiotensin converting enzyme (ACE) gene rs4362 polymorphism on the progression of kidney failure in patients with autosomal dominant polycystic kidney disease (ADPKD). Indian J Med Res (2016) 0.75
Clinical Manifestation and Management of ADPKD in Western Countries. Kidney Dis (Basel) (2016) 0.75
RBC deformability and amino acid concentrations after hypo-osmotic challenge may reflect chronic cell hydration status in healthy young men. Physiol Rep (2013) 0.75
Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2015) 0.75
Angiotensinogen gene polymorphisms and progression of chronic kidney disease in ADPKD patients. Clin Exp Nephrol (2015) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens (2008) 6.82
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol (2006) 4.72
Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol (2007) 2.71
A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int (1985) 2.52
High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis (2003) 2.41
Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev (2009) 2.17
Plasma sodium: ignored and underestimated. Hypertension (2004) 2.15
Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation (2009) 1.69
Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol (1995) 1.58
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2006) 1.53
Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int (2003) 1.45
Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab (2007) 1.39
The urgent need to reduce sodium consumption. JAMA (2007) 1.38
Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res (2001) 1.37
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol (2006) 1.37
A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol (2009) 1.31
Vascular consequences of dietary salt intake. Am J Physiol Renal Physiol (2009) 1.25
Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. Am J Physiol Regul Integr Comp Physiol (2006) 1.19
Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.16
Ouabain binds with high affinity to the Na,K-ATPase in human polycystic kidney cells and induces extracellular signal-regulated kinase activation and cell proliferation. J Am Soc Nephrol (2006) 1.15
Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease. Kidney Int (2008) 1.14
Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int (2009) 1.09
Role of sodium intake in the progression of chronic kidney disease. J Ren Nutr (2009) 1.02
The Yin and Yang of lactosylceramide metabolism: implications in cell function. Biochim Biophys Acta (2007) 1.00
Abnormalities of glycosphingolipid, sulfatide, and ceramide in the polycystic (cpk/cpk) mouse. J Lipid Res (1994) 0.99
Anti-atherogenic actions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I. Endocr J (2008) 0.97
TGF-beta mediated epithelial-mesenchymal transition in autosomal dominant polycystic kidney disease. Yonsei Med J (2009) 0.88
Hormonal responses to gradual changes in dietary sodium intake in humans. Am J Physiol (1989) 0.83
Identification of apolipoproteinA1 reduction in the polycystic kidney by proteomics analysis of the Mxi1-deficient mouse. Proteomics (2009) 0.81
Effects of changes in dietary sodium intake on plasma brain natriuretic peptide levels in patients with autosomal dominant polycystic kidney disease. J Hum Hypertens (1996) 0.78
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science (2009) 10.78
Regulation of cellular metabolism by protein lysine acetylation. Science (2010) 10.55
Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med (2014) 10.48
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Volume progression in polycystic kidney disease. N Engl J Med (2006) 7.16
Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science (2010) 6.04
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int (2003) 4.84
Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol (2006) 3.84
Quality of care for children in commercial and Medicaid managed care. JAMA (2003) 3.60
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Incidental findings in imaging research: evaluating incidence, benefit, and burden. Arch Intern Med (2010) 3.40
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2007) 3.26
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res (2008) 2.94
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension (2012) 2.86
Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell (2011) 2.84
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol (2005) 2.66
Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int (2004) 2.55
Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology (2010) 2.55
Hydrogen exchange methods to study protein folding. Methods (2004) 2.47
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43
Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41
Relationship between staff perceptions of hospital norms and hospital-level end-of-life treatment intensity. J Palliat Med (2007) 2.39
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int (2012) 2.39
Prevalence of urinary tract infection in childhood: a meta-analysis. Pediatr Infect Dis J (2008) 2.38
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol (2005) 2.37
Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore) (2006) 2.34
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int (2003) 2.32
Determination of split renal function by 3D reconstruction of CT angiograms: a comparison with gamma camera renography. AJR Am J Roentgenol (2008) 2.30
Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 2.28
Controversies in the management of vesicoureteral reflux: the rationale for the RIVUR study. J Pediatr Urol (2009) 2.26
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Hemodialysis arteriovenous fistula maturity: US evaluation. Radiology (2002) 2.26
Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem (2004) 2.26
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2006) 2.21
Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Rep (2011) 2.20
Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res (2013) 2.15
Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med (2011) 2.14
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J (2009) 2.12
Cystin, a novel cilia-associated protein, is disrupted in the cpk mouse model of polycystic kidney disease. J Clin Invest (2002) 2.07
Perceived discrimination in health care and health status in a racially diverse sample. Med Care (2008) 2.06
Imaging of urethral disease: a pictorial review. Radiographics (2004) 2.06
DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res (2013) 2.01
Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet (2004) 1.96
Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int (2012) 1.93
Total and intraabdominal fat distribution in preadolescents and adolescents: measurement with MR imaging. Radiology (2007) 1.92
Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant (2004) 1.90
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
IgE stimulates human and mouse arterial cell apoptosis and cytokine expression and promotes atherogenesis in Apoe-/- mice. J Clin Invest (2011) 1.77
Rationale and design issues of the Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR) study. Pediatrics (2008) 1.68
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension (2008) 1.66
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population. Atherosclerosis (2011) 1.64
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol (2011) 1.63
Association of inorganic arsenic exposure with type 2 diabetes mellitus: a meta-analysis. J Epidemiol Community Health (2013) 1.63
Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol (2010) 1.63
Differential renal function estimation using computerized tomography based renal parenchymal volume measurement. J Urol (2010) 1.62
The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol (2010) 1.59
Cystic and inherited kidney diseases. Am J Kidney Dis (2003) 1.59
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension (2012) 1.59
Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int (2008) 1.58